A5081590756- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Neuroscience of respiration and sleep
- Heart Failure Treatment and Management
- Medication Adherence and Compliance
- Antiplatelet Therapy and Cardiovascular Diseases
- Bone health and osteoporosis research
- Gothic Literature and Media Analysis
- Epilepsy research and treatment
- Shakespeare, Adaptation, and Literary Criticism
- Healthcare cost, quality, practices
- Asthma and respiratory diseases
- Bone Metabolism and Diseases
- Neonatal Respiratory Health Research
- Acute Myocardial Infarction Research
- Cardiac electrophysiology and arrhythmias
- Bone health and treatments
- Acute Ischemic Stroke Management
Leibniz Institute for Prevention Research and Epidemiology - BIPS
2020-2024
Hospital for Sick Children
2006
Abstract Aims To assess persistence and adherence to non-vitamin K antagonist oral anticoagulant (NOAC) treatment in patients with atrial fibrillation (AF) five Western European healthcare settings. Methods results We conducted a multi-country observational cohort study, including 559 445 AF initiating NOAC therapy from Stockholm (Sweden), Denmark, Scotland, Norway, Germany between 2011 2018. Patients were followed their first prescription until they switched vitamin antagonist, emigrated,...
Atrial fibrillation (AF) is a risk factor for brain infarction, which can lead to epilepsy. We aimed investigate whether treatment of AF with direct oral anticoagulants (DOACs) affects the epilepsy in comparison vitamin K antagonist phenprocoumon (PPC).We performed an active comparator, nested case-control study based on German Pharmacoepidemiological Research Database that includes claims data from statutory health insurance providers about 25 million persons since 2004. In 2011-17, 227 707...
Background The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice. Methods Cohorts were created using electronic healthcare databases from UK, Netherlands, Germany Sweden. Patients with a first prescription antagonist during period December 2011 (in January 2012) to 2017 Germany, 2016) indication, no record atrial...
We studied the characteristics of patients prescribed osteoporosis medication and patterns use in European databases. Patients were mostly female, older, had hypertension. There was suboptimal persistence particularly for oral medications. Our findings would be useful to healthcare providers focus their resources on improving specific treatments.To characterise therapy describe drug utilization patterns.We investigated treatment bisphosphonates, denosumab, teriparatide, selective estrogen...
Validation of outcomes allows measurement and correction for potential misclassification targeted adjustment algorithms case definition. The purpose our study was to validate identifying cases acute myocardial infarction (AMI), stroke, cardiovascular (CV) death using patient profiles, ie, chronological tabular summaries relevant available information on a patient, extracted from pseudonymized German claims data.Based the Pharmacoepidemiological Research Database (GePaRD), 250 were randomly...
Use of the direct oral anticoagulant rivaroxaban has strongly increased in Europe since its market approval for non-valvular atrial fibrillation 2011. Patients characteristics initiators may have changed over time but this not been investigated so far. We aimed to describe trends patient baseline among new users with from 2011 2016/17 two European countries. used data Germany (German Pharmacoepidemiological Research Database) and Netherlands (PHARMO Database Network). included (i) a first...
The safety and effectiveness of rivaroxaban versus vitamin K antagonists (standard care [SOC]) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) was evaluated Europe.
Purpose: Over the last decade, use of direct oral anticoagulants (DOACs) has strongly increased. We aimed to describe and compare risk profiles including potential changes over time among persons with non-valvular atrial fibrillation initiating treatment different DOACs or phenprocoumon (vitamin K antagonist) between 2011 2019 in Germany. Patients Methods: Using German Pharmacoepidemiological Research Database (GePaRD; claims data ~20% population), we identified a first dispensing DOAC...
Abstract Background The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice. Methods Cohorts were created using healthcare databases from UK, Netherlands, Germany Sweden. Patients given a first prescription antagonist during period December 2011 (in January 2012) to 2017 Germany, 2016) indication, with no record atrial...